Boehringer Ingelheim Pharmaceuticals, Inc. Release: Dabigatran Etexilate as Effective and Safe as Enoxaparin in Preventing Venous Thromboembolism (VTE) After Total Hip Replacement Surgery and Significantly Reduced the Combined Endpoint of Major VTE and VT

INGELHEIM, Germany--(BUSINESS WIRE)--For NON-US Healthcare Media Only

Data from the RE-NOVATE® II study presented today at the 15th Annual Congress of the European Hematology Association (EHA) have shown that dabigatran etexilate 220mg once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) after total hip replacement surgery. The results also showed that dabigatran etexilate significantly reduced the combined endpoint of major VTE and VTE-related death compared to enoxaparin.1